Clinical evaluation of steroid receptors in ovarian neoplasms

Abstract

Estrogen and progesterone receptors were estimated in a total of 25 ovarian neoplasms. None of the benign tumors showed steroid receptors. In malignant tumors serous tumors were more often receptor positive than the mucinous. Receptor levels were correlated with the staging of the disease, menstrual status and the resectability of the tumor. The response to chemotherapeutic drugs was better in patients with low estrogen and progesterone receptors as compared to those with high levels. The latter group showed a definite response to progesterone treatment in vitro. These are the group of patients who may benefit by combination of hormones and chemotherapeutic drugs.

CLINICOPATHOLOGICAL ANALYSIS OF OVARIAN TUMOURS IN A TERTIARY CARE INSTITUTE AND THE ROLE OF ER, PR AND HER-2/neu IN SURFACE EPITHELIAL TUMOURS OF OVARY

“…In our study, ER expression is positive in 4/11 cases (36.3%) cases, PR expression is positive in 5/11 (45.4%), which coincides with study of Sylvia et al [27] ER, PR has strong expression in endometrioid (2/3, 66.6%) and high-grade serous tumours (3/5 cases, 80%) which is similar to findings of Agarwal et al [28] Damia et al [29] This is in contrast to Buchynska et al [30] , who stated that ER expression is lower in high-grade tumour. The above features suggest possible mitogenic role of ER in ovarian tumours and high PR positivity in conjunction with ER expression is indicative of oestrogen regulated disease.…”

Ovarian Neoplasms: Histopathological Patterns and Estrogen and Progesterone Receptor Expression in Epithelial Ovarian Tumors

“…[21] Agarwal et al reported that receptor positivity increases with stage of tumour. [20] Similar observations were made by Sylvia et al…”

“…Hence ER/PR expression was more among postmenopausal patients as compared to premenopausal patients. Similar results were found in studies conducted by Sylvia et al, Hahnel et al and Agarwal et al [18][19][20] As per staging, ER was expressed as 66.66% in stage III, 66.66% in stage II, 50% in stage I. PR was expressed as 100 % in stage III, 100% in stage II and 25% in stage I. Hogdall E V et al reported that ER positivity in ovarian cancers increases with increasing FIGO stage. [21] Agarwal et al reported that receptor positivity increases with stage of tumour.…”

“…[20] ER+ ve PR +ve, ERve PR+ve phenotype predicts a favourable tumor biology and long term survival, probably reflecting functional effects on tumor proliferation, differentiation, and cellular apoptosis. [9] The present study aims at studying the histopathological pattern ,incidence of ovarian neoplasms and ER, PR expression in them which can be helpful in choosing Section: Pathology an appropriate hormonal therapy in hormone dependant tumours.…”

Estrogen and Progesterone Receptor Status as Prognostic Indicators in Patients with Optimally Cytoreduced Stage IIIc Serous Cystadenocarcinoma of the Ovary

“…Agarwal et al [18] reported that low ER status correlated important, depending on the stage of the tumor. Glavind and Grove [14] reported that ER status varied significantly with an increasing response to chemotherapy, although this finding did not retain statistical significance in regard to among the various epithelial ovarian cancers.…”